Showing 7481-7490 of 9550 results for "".
- FDA Approves Varithena to Treat Varicose Veinshttps://practicaldermatology.com/news/20131127-fda_approved_varithena_to_treat_varicose_veins/2459401/The FDA recently approved BTG plc's Varithena (polidocanol injectable foam) for the treatment of patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system. V
- ASLMS Announces Dr. Horace Furumoto Award Recipientshttps://practicaldermatology.com/news/20131126-laser_society_announces_dr_horace_furumoto_award_recipients/2459402/Michael H. Slayton, Ph.D. and Ishan Barman, Ph.D. will receive the Horace Furumoto Innovations Professional Development Awards at the upcoming meeting of the American Society for Laser Medicine & Surgery, Inc. (ASLMS), which will be held in April 2014, in Phoenix, AZ. Dr. Thomas Rohrer, Chair of the
- Caliber Imaging & Diagnostics Appoints Robert P. Fischmann VP of Operationshttps://practicaldermatology.com/news/20131125-caliber_imaging__diagnostics_appoints_robert_p_fischmann_vp_of_operations/2459406/Caliber Imaging & Diagnostics, formerly Lucid, Inc., has appointed Robert P. Fischmann to the role of Vice President of Operations, a newly created position. Mr. Fischmann's responsibilities at
- Investigational Melanoma Agent Improves Survival in Phase III Trialhttps://practicaldermatology.com/news/20131120-investigational_melanoma_agent_improves_survival_in_phase_iii_trial/2459408/Interim results from a pivotal Phase III trial show that Amgen's investigational agent talimogene laherpaepvec increased overall survival in patients with unresected stage IIIB, IIIC, or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF). The study found that median ov
- Actelion Launches Valchlor to Treat Stage IA and IB Mycosis Fungoides-type Cutaneous T-cell Lymphomahttps://practicaldermatology.com/news/20131119-actelion_launches_valchlor_to_treat_stage_ia_and_ib_mycosis_fungoides-type_cutaneous_t-cell_lymphoma/2459409/The FDA approved Actelion's Valchlor (mechlorethamine), the first and only FDA-approved topical formulation of mechlorethamine. Valchlor, a gel that is applied topically once a day, is an alkylating drug indicated to treat p
- Signum Dermalogix Receives Grant for the Development of Atopic Dermatitis Therapeuticshttps://practicaldermatology.com/news/20131114-signum_dermalogix_receives_grant_for_the_development_of_atopic_dermatitis_therapeutics/2459415/The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Signum Dermalogix, Inc. (Dermalogix) a Small Business Innovat
- Cosmetic Surgery Forum Announces Innovators in Dermatology Recipientshttps://practicaldermatology.com/news/20131107-cosmetic_surgery_forum_announces_innovators_in_dermatology_recipients/2459420/The upcoming Cosmetic Surgery Forum (www.cosmeticsurgeryforum.com), taking place at the ARIA Resort and Casino in Las Vegas from December 5-7, recently announced the recipients of its “Innovators in Dermatology” presentation. Among those honored this year will be Jim Hartman, Vice President of US Ae
- Onset Dermatologics Acquires Worldwide Rights to Clindagel from Galderma Laboratorieshttps://practicaldermatology.com/news/20131031-onset_dermatologics_acquires_worldwide_rights_to_clindagel_from_galderma_laboratories/2459425/Onset Dermatologics, LLC recently announced the acquisition of Clindagel (clindamycin phosphate gel 1%), a prescription topical antibiotic for the treatment of acne, from Galderma Laboratories. Clindagel is the only FDA-approved topical form
- Subliminally Exposed to be Presented at Cosmetic Surgery Forumhttps://practicaldermatology.com/news/20131029-subliminally_exposed_to_be_presented_at_cosmetic_surgery_forum/2459426/Based on the New York Times and USA Today best seller, Subliminally Exposed, Dr. Steven Dayan and Valerie Monroe will present at this year's Cosmetic Surgery Fo
- New Stelara Data Show Inhibition Of Joint Destruction In Psoriatic Arthritis Patientshttps://practicaldermatology.com/news/20131029-new_stelara_data_show_inhibition_of_joint_destruction_in_psoriatic_arthritis_patients/2459427/New findings from two integrated Phase III Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with ustekinumab (Stelara) resulted in